Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Taken together, combining an SGLT-2 inhibitor with a GLP-1 receptor agonist in people with type 2 diabetes is associated with lower risk of major cardiovascular events, mortality, heart failure hospitalisations and adverse kidney outcomes compared with monotherapy based on a meta-analysis of 18 cohort studies with 1,164,774 participants [36]
Currently, there is only one drug in this class of medicationstirzepatide, which is approved as Mounjaro for treatment of Type 2 diabetes and as Zepbound for the treatment of obesity
Garczorz W, Gallego-Colon E, Kosowska A, Kych-Ratuszny A, Woniak M, Marcol W, Niesner KJ, Francuz T
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, ONeil PM, Rubino DM, Skovgaard D
Cardiovasc.Drugs Ther 2009;23(4):301-306
US$ 20.69
US$ 24.34
US$ 24.79
US$ 21.29
US$ 23.11
US$ 24.90
US$ 28.42
